Facing the Challenges in Vaccine Upstream Bioprocessing - 15

ROUNDUP

Integrated Continuous
Manufacturing of Biologics:
Trends in the Field
Biosimilar Manufacturers, Take Note:
This Stream Is for You

ADDITIONAL CONTENT

Randi Hernandez

15

| GENengnews.com

During upstream bioprocess development
bioprocess engineers need to decide between a
batch, fed-batch or continuous/perfusion process.
Analyzing the benefits of their respective usage at
bench scale allows confident process decisions.
Watch Webinar

reptile8488/Getty Images

A

lthough estimates vary slightly, many industry experts predict continuous manufacturing will, at the least, cut the cost of manufacturing biologics in half. Thus, it will be an
attractive option for drug makers looking to trim
manufacturing budgets. But not all biologics
would be feasible candidates for a truly integrated processing stream, and a truly continuous line
may require a larger initial capital investment.

To learn more about which companies and
products will likely incorporate continuous
manufacturing first-and to understand which
"hot-button" questions regarding implementation still require attention and clarification-GEN
spoke to pioneers in the field of continuous
biomanufacturing, including Massimo
Morbidelli, Ph.D., professor of chemical reaction
engineering at the Institute for Chemical and
Bioengineering at ETH Zürich; Andrew Zydney,



https://www.eppendorf.com/US-en/service-support/eppendorf-training-center/webinars/recorded-webinars/optimizing-a-biosimilar-production-process http://www.GENengnews.com

Facing the Challenges in Vaccine Upstream Bioprocessing

Table of Contents for the Digital Edition of Facing the Challenges in Vaccine Upstream Bioprocessing

Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 1
Facing the Challenges in Vaccine Upstream Bioprocessing - 2
Facing the Challenges in Vaccine Upstream Bioprocessing - 3
Facing the Challenges in Vaccine Upstream Bioprocessing - Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 5
Facing the Challenges in Vaccine Upstream Bioprocessing - 6
Facing the Challenges in Vaccine Upstream Bioprocessing - 7
Facing the Challenges in Vaccine Upstream Bioprocessing - 8
Facing the Challenges in Vaccine Upstream Bioprocessing - 9
Facing the Challenges in Vaccine Upstream Bioprocessing - 10
Facing the Challenges in Vaccine Upstream Bioprocessing - 11
Facing the Challenges in Vaccine Upstream Bioprocessing - 12
Facing the Challenges in Vaccine Upstream Bioprocessing - 13
Facing the Challenges in Vaccine Upstream Bioprocessing - 14
Facing the Challenges in Vaccine Upstream Bioprocessing - 15
Facing the Challenges in Vaccine Upstream Bioprocessing - 16
Facing the Challenges in Vaccine Upstream Bioprocessing - 17
Facing the Challenges in Vaccine Upstream Bioprocessing - 18
Facing the Challenges in Vaccine Upstream Bioprocessing - 19
Facing the Challenges in Vaccine Upstream Bioprocessing - 20
Facing the Challenges in Vaccine Upstream Bioprocessing - 21
Facing the Challenges in Vaccine Upstream Bioprocessing - 22
Facing the Challenges in Vaccine Upstream Bioprocessing - 23
Facing the Challenges in Vaccine Upstream Bioprocessing - 24
Facing the Challenges in Vaccine Upstream Bioprocessing - 25
Facing the Challenges in Vaccine Upstream Bioprocessing - 26
Facing the Challenges in Vaccine Upstream Bioprocessing - 27
Facing the Challenges in Vaccine Upstream Bioprocessing - 28
Facing the Challenges in Vaccine Upstream Bioprocessing - 29
Facing the Challenges in Vaccine Upstream Bioprocessing - 30
Facing the Challenges in Vaccine Upstream Bioprocessing - 31
Facing the Challenges in Vaccine Upstream Bioprocessing - 32
Facing the Challenges in Vaccine Upstream Bioprocessing - 33
Facing the Challenges in Vaccine Upstream Bioprocessing - 34
Facing the Challenges in Vaccine Upstream Bioprocessing - 35
https://www.nxtbookmedia.com